Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics, Inc. (KYMR) is a clinical-stage biopharmaceutical company advancing targeted protein degradation therapies for immune-inflammatory diseases and oncology. This dedicated news hub provides investors and industry observers with timely updates on the company’s scientific progress, clinical developments, and strategic initiatives.
Access comprehensive coverage of KYMR’s innovative pipeline, including updates on STAT6 and IRAK4 degrader programs, partnership announcements, and financial disclosures. Our curated news collection enables efficient tracking of milestones in protein degradation research – from preclinical breakthroughs to clinical trial results – while maintaining strict adherence to factual reporting standards.
Key content categories include regulatory filings, peer-reviewed research highlights, executive leadership updates, and analysis of therapeutic platform advancements. All materials are sourced from verified channels to ensure reliability for investment research and sector analysis.
Bookmark this page for streamlined access to KYMR’s latest developments in transforming undruggable targets into viable treatment pathways through proprietary degradation technology. Check regularly for updates on oral small molecule therapies that aim to combine biologics-like efficacy with enhanced patient convenience.
Kymera Therapeutics (NASDAQ: KYMR) has scheduled a video webcast for May 9, 2025, from 10:00 a.m. to 11:30 a.m. ET. During this event, the clinical-stage biopharmaceutical company will:
- Present its Q1 2025 financial results
- Unveil a new oral development candidate targeting an undrugged target for autoimmune and rheumatic diseases
- Review highlights and upcoming milestones of its immunology pipeline
The webcast will be accessible through registration and available for replay on the company's website under the Investors section.
Kymera Therapeutics (NASDAQ: KYMR) has initiated dosing in its BroADen Phase 1b clinical trial for KT-621, a first-in-class oral STAT6 degrader, targeting moderate to severe atopic dermatitis (AD). The trial will evaluate approximately 20 adult patients with once-daily dosing for 28 days, focusing on safety, tolerability, and clinical activity.
The company has completed SAD/MAD dosing in the Phase 1 healthy volunteer trial, with data expected in June 2025. The BroADen trial results are anticipated in Q4 2025. Additionally, Kymera plans to launch two parallel Phase 2b trials: one for AD in Q4 2025 and another for asthma in Q1 2026.
The BroADen study aims to demonstrate that STAT6 degradation in blood and skin by KT-621 produces effects similar to dupilumab in reducing Th2 biomarkers. The trial will assess clinical endpoints including Eczema Area and Severity Index (EASI) and pruritus numerical rating scale (NRS).
Kymera Therapeutics (NASDAQ: KYMR) has appointed Noah Goodman, M.B.A., as Chief Business Officer to lead business development strategy and activities. Goodman brings extensive life sciences industry experience, having previously served as President and Chief Business Officer at Chroma Medicine and nChroma Bio through their merger with Nvelop Therapeutics.
Prior to joining Kymera, Goodman held key positions at several biotech companies, including Executive Director roles at Cadent Therapeutics (later acquired by Novartis) and Seres Therapeutics, where he led collaborations and licensing transactions. His earlier experience includes business development at Spark Therapeutics and consulting at Easton Associates.
The appointment aligns with Kymera's mission to develop oral small molecule degrader medicines for immunological diseases and build a fully integrated biopharmaceutical company.
Kymera Therapeutics (NASDAQ: KYMR) reported its Q4 and full year 2024 financial results, highlighting significant progress in its immunology pipeline. The company maintains a strong financial position with $851 million in cash as of December 31, 2024, providing runway into mid-2027.
Key pipeline updates include: KT-621 (STAT6) Phase 1 trial data expected June 2025, with Phase 1b trial in atopic dermatitis starting Q2 2025; KT-295 (TYK2) Phase 1 trial initiating Q2 2025; and ongoing KT-474/SAR444656 (IRAK4) Phase 2b trials in partnership with Sanofi.
Financial results show collaboration revenues of $7.4 million for Q4 2024 and $47.1 million for full-year 2024. Net loss was $70.8 million for Q4 and $223.9 million for the full year. R&D expenses increased to $240.2 million for 2024, reflecting investment in pipeline development.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, has announced its participation in several key investor conferences in March 2025.
The company will engage in fireside chats at the following events:
- TD Cowen 45th Annual Healthcare Conference in Boston (March 5, 9:10 a.m. ET)
- Leerink Partners Global Biopharma Conference in Miami (March 11, 8:00 a.m. ET)
- Jefferies Biotech on the Bay Summit in Miami (March 12, one-on-one meetings)
- H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (March 27, 10:30 a.m. ET)
Live webcasts will be accessible through the Investors section of Kymera's website, with replays available after the events.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines, has announced it will release its fourth quarter and full year 2024 financial results on February 27, 2025. The company will host a video conference call at 8:30 a.m. ET on the same day. Investors can access the video call through registration or view the livestreamed webcast in the 'News and Events' section of Kymera's website. A replay of the webcast will be available after the event.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines, has announced its participation in two major investor conferences in February 2025.
The company will engage in fireside chats at the Guggenheim SMID Cap Biotechnology Conference in New York on February 6 at 10:00 a.m. ET, and the Oppenheimer 35th Annual Healthcare Life Sciences Conference, a virtual event, on February 11 at 11:20 a.m. ET.
Live webcasts of both presentations will be accessible through the Investors section under "News and Events" on Kymera's website (www.kymeratx.com). Recordings will be archived and available for viewing after the events.
Kymera Therapeutics (NASDAQ: KYMR) has outlined its key objectives for 2025, focusing on advancing its oral immunology programs. The company's lead candidate, KT-621, a STAT6 degrader, is in Phase 1 trials with data expected in Q2 2025, followed by Phase 1b trials in atopic dermatitis. Their KT-295 TYK2 degrader will advance to Phase 1 testing in Q2 2025, while KT-474/SAR444656 Phase 2b studies in hidradenitis suppurativa and atopic dermatitis are ongoing.
The company plans to disclose a novel oral immunology program in H1 2025. With an estimated $850 million in cash, Kymera has runway into mid-2027. Their strategy focuses on developing oral drugs with biologics-like activity for treating inflammatory diseases, particularly targeting conditions like atopic dermatitis, asthma, and other Th2-driven diseases affecting over 130 million patients globally.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines, has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 14, 2025, at 9:00 a.m. PT/12:00 p.m. ET in San Francisco, California.
The company's Founder, President and CEO, Nello Mainolfi, PhD, will present an overview of Kymera's progress and outline anticipated milestones for 2025. Interested parties can access a live webcast of the presentation and Q&A session through the 'News and Events' section of Kymera's investor relations website. The presentation recording will be archived and available for later viewing.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on targeted protein degradation, has announced its participation in two major investor conferences this December. The company will engage in fireside chats at the Piper Sandler 36th Annual Healthcare Conference in New York on December 3 at 1:00 p.m. ET, and the 7th Annual Evercore ISI HealthCONx Conference in Coral Gables on December 4 at 4:15 p.m. ET. Live webcasts will be available on Kymera's website under the Investors section, with replays accessible after the events.
